Center on Health Equity & Access

Clinical

Health Care Cost

Health Care Delivery

Insurance

Policy

Technology

Value-Based Care

News

All News

Press Releases

Product Approvals and Launches

Video

All Video Types

AJMC TV

Guidelines

Insights

OnLocation

Payer Perspectives

Peer Exchange

Post Conference Perspectives

Stakeholder Summit

Podcasts

Journals

All Journals

The American Journal of Managed Care

Population Health, Equity & Outcomes

Evidence-Based Oncology

About Supplements and Featured Publications

Supplements and Featured Publications Issues

Submit a Manuscript

Conferences

Conference Coverage

Conference Listing

Events

Institute for Value-Based Medicine

Patient-Centered Oncology Care

Resources

Interactive Tools

Formulary Central

Clinical Spotlight

Microsites

About AJMC

AJMC Staff

Anniversary

Seema Sonnad Award

Strategic Alliance Partners

Subscribe

Maggie is a senior editor for The American Journal of Managed Care® (AJMC®) and produces written, video, and podcast content covering several disease states. She joined AJMC® in 2019, and has been with AJMC®’s parent company, MJH Life Sciences®, since 2014, when she started as a copy editor.

She has a BA in English from Penn State University. You can connect with Maggie on 

Articles

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

CLL Breakthrough: 100% Efficacy Reported for VenR Retreatment

. Her work focuses on disparities and systemic inequities in care and access to the health system, as well as the impacts of health policy on various racial, gendered, and socioeconomic communities. She seeks perspectives from experts in internal medicine, health equity, community outreach, clinical research, mental health, and legislative policy.

, she delved into rare disease coverage at HCPLive

, a sister publication, where she fostered connections that extended beyond the research community into that of health advocacy, paving the way to her current role. Her work has been featured in 

NewsBreak, CHEST Today, Contemporary Pediatrics, Contemporary OB/GYN, Dermatology Times, Drug Topics, Managed Healthcare Executive, RamaOnHealthcare, and CGTLive.

A Maui Derm 2026 session explored advancements in pediatric dermatology, emphasizing precision medicine and targeted therapies for children.

Advances in Pediatric Dermatology Spotlight Diagnostic Precision and New Systemics

Speakers delved into innovative strategies in skin tumor management, focusing on chemotherapies, patient risk assessment, and evolving treatment protocols.

Optimizing Nonsurgical Management of Skin Tumors at Maui Derm 2026

Julia is an associate editor for The American Journal of Managed Care® (AJMC®) and joined AJMC® in 2022. She produces written and video content covering multiple disease states, and assists in the screening process for manuscripts submitted to AJMC®.

She has a BA in English language and literature from Rutgers University. You can connect with Julia on 

The upcoming price negotiations are the third cycle since the Inflation Reduction Act was passed in 2022.

Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

About

Contact

Editorial Boards

Advertise

Do Not Sell My Information

Terms & Conditions

Privacy Policy

AJMC - Managed Care News, Research, and Expert Insights

Facebook

LinkedIn

Instagram

Specialty Area

Biosimilars

Cardiorenalmetabolic

Dermatology

Gastroenterology

Hematology

Hepatology

Immunology

Infectious Disease

Mental Health

Neurology

Obesity

Oncology

Ophthalmology

Pulmonology

Rare Disease

Respiratory

Rheumatology

Women's Health

Spotlight

Free In-Person Regional Events Focused on Oncology and Population Health

Topics

Digital Health

Formulary

Gene Therapy

Health Care Administration

Population Health

All Coverage

Event Coverage

Interviews

AJMC Journals

Author Forms

Authors

Nominate a Rising Leader

View


Medical Director
Department of Hematology and Medical Oncology
Texas Oncology
Fort Worth Cancer Center
Fort Worth, TX

These faculty have disclosed the following relevant commercial financial relationships or affiliations in the past 12 months.

CONSULTANCIES OR PAID ADVISORY BOARDS
AVEO Pharmaceuticals
Eli Lilly
Johnson & Johnson
Pharmacyclics
Sanofi


HONORARIA
AVEO Pharmaceuticals
Eli Lilly
Johnson & Johnson
Pharmacyclics
Sanofi


LECTURE FEES FOR SPEAKING AT THE INVITATION OF A COMMERCIAL SPONSOR
AVEO Pharmaceuticals
Eli Lilly
Johnson & Johnson
Pharmacyclics
Sanofi

Dr. Asad Dean, the Medical Director at Texas Oncology, Fort Worth Cancer Center, has disclosed his commercial financial relationships over the past year. He has served on consultancies or paid advisory boards for AVEO Pharmaceuticals, Eli Lilly, Johnson & Johnson, Pharmacyclics, and Sanofi. Additionally, he has received honoraria and lecture fees from these same companies for speaking engagements. These disclosures are important for transparency and to understand potential conflicts of interest in his professional activities and affiliations.

Participating Faculty: Immune Thrombocytopenia: Contemporary Pathophysiology, Treatment Gaps, and the Role of Novel Mechanisms in Patient-Centered Care

Immune Thrombocytopenia: Contemporary Pathophysiology, Treatment Gaps, and the Role of Novel Mechanisms in Patient-Centered Care

Supplements and Featured Publications

Participating Faculty: Immune Thrombocytopenia: Contemporary Pathophysiology, Treatment Gaps, and the Role of Novel Mechanisms in Patient-Centered Care

Faculty

Faculty Disclosures